The antiviral drug ensitrelvir reduced COVID-19 infection risk by two-thirds in household contacts when administered within 72 hours of symptom onset in the index patient, according to a Phase III randomized controlled trial.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Antiviral ensitrelvir cuts risk of COVID-19 in household contacts by two-thirds, study finds
66 % Risk reduction
72 Hours After Symptom Onset Treatment window
Phase III Randomized Controlled Trial Study design
72 Hours treatment window